Rosemont Acquires Lucis Pharma
Rosemont Pharmaceuticals (Rosemont) announced that it has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition, Rosemont will expand its existing portfolio and access a pipeline of innovative products, providing life-saving medicines to the UK and overseas markets.
Founded in 2012, Lucis has grown into a leading provider of development and licensing of new and specialty medicines. With more than a dozen products spanning a variety of therapeutic areas, Lucis has built a strong portfolio that serves the growing patient need for liquid medicines in addition to innovative developments.
The acquisition will also allow Rosemont to expand its portfolio and enter unit-dose or sachet markets through emerging products, while also growing its business through key Lucis product launches in 2021/22.
“As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets.
We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practice for their care” says Howard Taylor, Chief Executive Officer of Rosemont.
Rosemont has more than 50 years of experience in new, prescription, oral liquid medicine and has one of the largest product portfolios in the world, with more than 130 oral liquid medicines addressing a variety of therapeutic areas such as heart health, endocrinology and pain management.
